Moreover, knocking down CCR2 abrogated PCa invasiveness to the bone, whereas, in an in vivo model of PCa metastasis, inhibiting CCL2 activity with neutralizing antibodies decreased the overall tumor burden [490,491]. The gene discussed is CCR2; the disease is neoplasm.